Biotech Values

[DewDiligence]

Vosevi’s US list price=$74,760 for 12 weeks—identical to Epclusa’s US list price for 12 weeks. I.e., GILD is charging no list-price premium for the voxilaprevir component of Vosevi; however, Vosevi’s US ASP (after discounts and rebates) could be somewhat higher than Epclusa’s.

In any case, Vosevi's list price should give ABBV/ENTA's G/P plenty of room for maneuvering in the US market, assuming that G/P is approved with an 8-week option for most patients.